Abstract：Objective: To evaluate the clinical efficacy of moxifloxacin sequential therapy on patients with healthcareassociated pneumonia(HCAP). Methods: Sixty-two patients with HCAP hospitalized from January 2010 to January 2013 in the emergency ward of Shanghai Gongli Hospital were randomly divided into two groups, the treatment group(n=31) was administrated 0.4 g moxifloxacin intravenously, once a day, took the same medicine orally when the symptoms were improved, with total treatment course of 8~12 d; and the control group(n=31) was administrated 2.0 g cefotiam intravenously, twice a day, with total treatment course of 10~14 d. The efficacy of two groups was compared. Results: The clinical curative effect rates of moxifloxacin and cefotiam were 93.5% and 71.0%, the bacterial clearance rates were 94.7% and 61.1%, respectively; moxifloxacin was better than cefotiam in clinical curative effect(P<0.05). Conclusion: The anti-infection function of moxifloxacin sequential therapy was effective, meanwhile, with high bacterial clearance rate and clinical value.
收稿日期: 2014-02-14
作者简介: 陈佩丽(1977—)，女，上海人，主治医师，主要从事急诊医学的研究。
引用本文:
陈佩丽，郭东风，许晓春. 莫西沙星序贯治疗卫生保健相关性肺炎疗效观察[J]. 江苏大学学报:医学版, 2014, 24(02): 142-144.
CHEN Pei-li, GUO Dong-feng, XU Xiao-chun. Clinical observation on moxifloxacin sequential therapy for healthcare-associated pneumonia. Journal of Jiangsu University(Medicine Edition), 2014, 24(02): 142-144.
\[1\]姚瑜.美国传染病学会/美国胸科学会联合颁布的2007年修订版成人社区获得性肺炎诊疗指南执行概要\[J\]．国外医药：抗生素分册，2008，29(2)：80-87．\[2\]吴均竹，周作华，吕军眉，等．呼吸道感染病原菌分布及培养结果分析\[J\]．实用诊断与治疗杂志，2007，21(5)：386-387．\[3\]Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin\[J\]．Drugs Today(Brac), 2000, 36(4)：229-244．\[4\]American Thoracic Society， Infectious Diseases Society of American. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcareassociated pneumonia\[J\]．Am J Respir Crit Care Med, 2005,171(4): 388-416．\[5\]蔡柏蔷，李龙芸．协和呼吸病学\[M\]．北京：中国协和医科大学出版社， 2005：165-172．\[6\]Wilson R,Macklin-Doherty A. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis\[J\]．Expert Rev Respir Med, 2012, 6(5)：481-492．\[7\]Lopes SC, Ribeiro C, Gameiro P. A new approach to counteract bacteria resistance: a comparative study between moxifloxacin and a new moxifloxacin derivative in different model systems of bacterial membrane\[J\]．Chem Biol Drug Des, 2012, 81(2)：265-274．\[8\]陈玉玲，邵华军，张文辉，等．卫生保健相关性肺炎的临床分析\[J\]．中国感染与化疗杂志，2009，9(4)：256-259．\[9\]Miravitlles M, Anzueto A．Moxifloxacin：a respiratory fluoroquinolone\[J\]．Expert Opin Pharmacother, 2008, 9(10): 1755-1772．\[10\]Wilson R,Anzueto A,Miravitlles M, et al．Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results\[J\]．Eur Respir J, 2012, 40(1)：17-27．\[11\]McDonald LC．Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment\[J\]．Clin Infect Dis, 2006, 42(Suppl 2)：S65-S71.
2014, Vol. 24 
